Tuesday, 07 Apr 2020

You are here

Best of 2019 - Are Non-TNF Biologics Superior to TNF inhibitors?

Current ACR and EULAR guidelines list TNF-inhibitors (TNFi) abatacept, rituximab, and tocilizumab as being equally effective after methotrexate or as second line therapies when treating rheumatoid arthritis. An analysis from the Swedish Rheumatology Register shows that the non-TNFi biologic DMARDs (bDMARDs), in particular tocilizumab and rituximab, are more effective than TNFi. 

RA patients in this registry were included if they initiated TNFi, rituximab, abatacept or tocilizumab between 2010–2016 as first bDMARD (n = 9333), or after switch from TNFi as first bDMARD (n = 3941).

Effectiveness was assessed 3 and 12 months based on the proportion remaining on therapy and with EULAR Good Response, HAQ improvement >0.2, zero swollen/tender joints and CDAI remission.

At 1 year, patients starting non-TNFi (vs TNFi) as first bDMARD had a higher proportion remaining on drug and reaching most response outcomes as first bDMARD (EULAR Good Response/HAQ improvement):

  • TNFi 24.9/25.4%
  • Rituximab 28.6/37.2%
  • Abatacept 31.9/33.7%
  • Tocilizumab 50.9/43.1%).

After switch from a first TNFi, rituximab and tocilizumab, but not abatacept, were associated with significantly better response measures than continuing TNFi (1-year EULAR Good Response/HAQ improvement):

  • TNFi 11.6/16.1%
  • Rituximab 24.8/33.2%
  • Abatacept 13.1/17.5%
  • Tocilizumab 34.1/29.4%)

While guidelines are based on metanalyses and expert consensus (and not head-to-head trials), these real world data suggest high efficacy when using non-TNFi bDMARDs, in particular tocilizumab and rituximab, as either the first bDMARD or as a switch candidate after TNFi.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

ACR Infusion Guidance During COVID-19 Crisis

The American College of Rheumatology (ACR) has published a guidance document on infusions and office based therapies.

Infusions in the Time of Coronavirus

As they say, necessity is the mother of invention. After years of bemoaning the challenges of telemedicine, our rheumatology clinic transition entirely to a remote clinic in the space of a week. One of the few good things to come out of this crisis is that we may learn that in-person visits are not as critical as we thought, which may in turn help our specialty’s access issues.

Earlier Anakinra Initiation Warranted in Still's Disease

An Italian study examined the outcomes in adult onset Still's disease (AOSD) based on whether they received early or delayed treatment with anakinra (ANK). 

A total of 141 AOSD patients were retrospectively studied.

Overall, they found no differences in efficacy if ANK was started within 6 (or 12 mos) vs. thereafter.  

Switching Biologics in JIA

While there are numerous agents approved for use in juvenile idiopathic arthritis, little is know about actual use biological disease-modifying antirheumatic drug (DMARD) use or switching in the biologic era. A cohort comparison study has shown that after an unsuccessful trial of a first biologic, changing to a second TNFi is as effective as switching to a non-TNFi biologic.

Tofacitinib Effective in Refractory Still's Disease

Fourteen cases reported from mainland China suggest that tofacitinib (TOFA) may be effective in patients with refractory adult-onset Still’s disease (AOSD), further adding to a growing list of potential use of JAK inhibition in managing inflammatory, and now autoinflammatory, disease.